Nano vs Resistant Tuberculosis: Taking the Lung Route
Tuberculosis (TB) is among the top 10 infectious diseases worldwide. It is categorized among the leading killer diseases that are the reason for the death of millions of people globally. Although a standardized treatment regimen is available, non-adherence to treatment has increased multi-drug resistance (MDR) and extensive drug-resistant (XDR) TB development. Another challenge is targeting the death of TB reservoirs in the alveoli via conventional treatment. TB Drug resistance may emerge as a futuristic restraint of TB with the scarcity of effective Anti-tubercular drugs. The paradigm change towards nano-targeted drug delivery systems is mostly due to the absence of effective therapy and increased TB infection recurrent episodes with MDR. The emerging field of nanotechnology gave an admirable opportunity to combat MDR and XDR via accurate diagnosis with effective treatment. The new strategies targeting the lung via the pulmonary route may overcome the new incidence of MDR and enhance patient compliance. Therefore, this review highlights the importance and recent research on pulmonary drug delivery with nanotechnology along with prevalence, the need for the development of nanotechnology, beneficial aspects of nanomedicine, safety concerns of nanocarriers, and clinical studies. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 24(2023), 8 vom: 04. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Deepika [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Extensive drug-resistant (XDR) |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1208/s12249-023-02708-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053972007 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053972007 | ||
| 003 | DE-627 | ||
| 005 | 20231230064630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231205s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-023-02708-3 |2 doi | |
| 035 | |a (DE-627)SPR053972007 | ||
| 035 | |a (SPR)s12249-023-02708-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Deepika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nano vs Resistant Tuberculosis: Taking the Lung Route |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Tuberculosis (TB) is among the top 10 infectious diseases worldwide. It is categorized among the leading killer diseases that are the reason for the death of millions of people globally. Although a standardized treatment regimen is available, non-adherence to treatment has increased multi-drug resistance (MDR) and extensive drug-resistant (XDR) TB development. Another challenge is targeting the death of TB reservoirs in the alveoli via conventional treatment. TB Drug resistance may emerge as a futuristic restraint of TB with the scarcity of effective Anti-tubercular drugs. The paradigm change towards nano-targeted drug delivery systems is mostly due to the absence of effective therapy and increased TB infection recurrent episodes with MDR. The emerging field of nanotechnology gave an admirable opportunity to combat MDR and XDR via accurate diagnosis with effective treatment. The new strategies targeting the lung via the pulmonary route may overcome the new incidence of MDR and enhance patient compliance. Therefore, this review highlights the importance and recent research on pulmonary drug delivery with nanotechnology along with prevalence, the need for the development of nanotechnology, beneficial aspects of nanomedicine, safety concerns of nanocarriers, and clinical studies. Graphical Abstract | ||
| 650 | 4 | |a extensive drug-resistant (XDR) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a multi-drug resistance (MDR) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a nanocarrier |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a nanomedicine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a tuberculosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Nirban, Sunita |4 aut | |
| 700 | 1 | |a Ojha, Smriti |4 aut | |
| 700 | 1 | |a Kumar, Tarun |4 aut | |
| 700 | 1 | |a Jain, Neha |4 aut | |
| 700 | 1 | |a Mohamad, Najwa |4 aut | |
| 700 | 1 | |a Kumar, Pradeep |4 aut | |
| 700 | 1 | |a Pandey, Manisha |0 (orcid)0000-0002-8249-9743 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d New York, NY : Springer, 2000 |g 24(2023), 8 vom: 04. Dez. |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:8 |g day:04 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-023-02708-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 8 |b 04 |c 12 | ||